Successful Anticoagulation with Dalteparin in a Patient with Mechanical Heart Valves

Abstract

Spanish

French

BACKGROUND:

Standard thromboprophylaxis of patients with mechanical heart valves is achieved using warfarin. In certain patients this may be very difficult; thus, alternative pharmacotherapy must be used.

OBJECTIVE:

To report a case of a patient who successfully used dalteparin, a low-molecular-weight heparin, for anticoagulation.

CASE SUMMARY:

A 58-year-old white woman with mechanical aortic and mitral heart valves initially received warfarin for anticoagulation. Thromboprophylaxis was very challenging. Her international normalized ratios (INRs) were erratic and occasionally responded paradoxically to changes in dose. Finally, she experienced a left hemispheric stroke when her INR was extremely subtherapeutic. Subsequently, despite best efforts, her INR again was subtherapeutic; warfarin was discontinued and dalteparin was initiated with daily self-administered subcutaneous injections of 16 000 units. No complications have arisen since initiation of the new pharmacotherapy approximately 18 months ago.

DISCUSSION:

The use of low-molecular-weight heparin for the treatment and prevention of venous thromboembolism is well described. There are few reports of its use for thromboprophylaxis of patients with mechanical heart valves. Our patient has been managed successfully with dalteparin.

CONCLUSIONS:

Dalteparin was effectively and safely used for the thromboprophylaxis of a patient with mechanical heart valves whose anticoagulation was previously difficult to manage with warfarin. Dalteparin deserves further study in patients who are unable to tolerate warfarin.

Keywords

mechanical heart valve warfarin low-molecular-weight heparin dalteparin

Get full access to this article

View all access options for this article.

References

Turpie

. Safer anticoagulant therapy after heart valve replacement. Recommendations for less intense regimens. Postgrad Med J 1997;101: 85–6,89–90,93–4.

Salzman

Merill

. Interaction of blood with artificial surfaces. In: Coleman

Hirsh

Marder

Salzman

, eds. Haemostasis and thrombosis: basic principles and clinical practice. 2nd ed. Philadelphia: JB Lippincott, 1987: 1335–47.

Larsen

Alexander

Stanford

. Thromboembolic phenomena in patients with prosthetic aortic valves who did not receive anticoagulants. Ann Thorac Surg 1977;23: 323–6.

Stein

Alpert

Copeland

Dalen

Goldman

Turpie

. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 1992;102 (4 suppl):445S–55S.

Hirsh

Dalen

Deykin

Poller

. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1992;102 (4 suppl):312S–26S.

Kumar

Haigh

Rhodes

Peaker

Davies

Roberts

Poor compliance is a major factor in unstable outpatient control of anticoagulant therapy. Thromb Haemost 1989;62:729–32.

O'Reilly

Rytand

. “Resistance” to warfarin due to unrecognized vitamin K supplementation. N Engl J Med 1980;303: 160–1.

Suttie

Mummah-Schendel

Shah

Lyle

Greger

. Vitamin K deficiency from dietary vitamin K restriction in humans. Am J Clin Nutr 1988;47: 475–80.

Hirsh

Dalen

Deykin

Poller

Bussey

. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1995;108 (4 suppl):231S–46S.

10.

Talstad

Gamst

. Warfarin resistance due to malabsorption. J Intern Med 1994;236: 465–7.

11.

Keréveur

Leclercq

Trossaërt

Dupeyron

Parent

Horellou

Vitamin K metabolism in a patient resistant to vitamin K antagonists. Haemostasis 1997;27:168–73.

12.

Hirsh

. Oral anticoagulant drugs. N Engl J Med 1991;324: 1865–75.

13.

Wells

Holbrook

Crowther

Hirsh

. Interactions of warfarin with drugs and food. Ann Intern Med 1994;121: 676–83.

14.

Harenberg

Huhle

Piazolo

Giese

Heene

. Long-term anticoagulation of outpatients with adverse events to oral anticoagulants using low-molecular-weight heparin. Semin Thromb Hemost 1997;23: 167–72.

15.

Kakkar

Cohen

Edmondson

Phillips

Cooper

Das

Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group. Lancet 1993;341: 259–65.

16.

Holm

Handeland

Abildgaard

Arnesen

Gottschalk

Subcutaneous heparin treatment of deep venous thrombosis: A comparison of unfractionated and low molecular weight heparin. Haemostasis 1986;16 (suppl 2):30–7.

17.

Lindmarker

Holmstrom

Granqvist

Johnsson

Lockner

. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994;72: 186–90.

18.

Wells

Kovacs

Bormanis

Forgie

Goudie

Morrow

Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: A comparison of patient self-injection with homecare injection. Arch Intern Med 1998;158:1809–12.

19.

Schrader

Stibbe

Armstrong

Kandt

Muche

Kostering

Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration. Kidney Int 1988;33:890–6.

20.

Lee

Liauw

. Low molecular weight heparin for thromboprophylaxis during pregnancy in 2 patients with mechanical mitral valve replacement. Thromb Haemost 1996;76: 628–30.

21.

Warkentin

Levine

Hirsh

Horsewood

Roberts

Gent

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330–5.

22.

Monreal

Lafoz

Olive

Del Rio

Vedia

. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994;71: 7–11.